Exportació completada — 

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

PURPOSE: One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB 40603 (Alliance), a 2 × 2 factorial, open-label, randomized phase II trial, evaluated the impact of adding carboplatin and/or bevac...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Sikov, William M., Berry, Donald A., Perou, Charles M., Singh, Baljit, Cirrincione, Constance T., Tolaney, Sara M., Kuzma, Charles S., Pluard, Timothy J., Somlo, George, Port, Elisa R., Golshan, Mehra, Bellon, Jennifer R., Collyar, Deborah, Hahn, Olwen M., Carey, Lisa A., Hudis, Clifford A., Winer, Eric P.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2015
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4268249/
https://ncbi.nlm.nih.gov/pubmed/25092775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.0572
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars